TRAW Traws Pharma, Inc.
Traws Pharma, Inc. (TRAW) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.8% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Traws Pharma, Inc.
Traws Pharma Inc. is involved in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Traws Pharma Inc., formerly known as Onconova Therapeutics Inc., is based in NEWTOWN, Pa.
Sector
Healthcare
Industry
Drug Manufacturers/Other